SAHPRA Approval of Lenacapavir: A Game-Changer in HIV Prevention
SAHPRA's recent approval of Lenacapavir marks a significant advancement in HIV prevention, providing an innovative option for at-risk populations.
Quick Answer
SAHPRA's recent approval of Lenacapavir marks a significant advancement in HIV prevention, providing an innovative option for at-risk populations.
Key Questions
- What is lenacapavir and how does it differ from daily oral PrEP?
- What clinical evidence supports SAHPRA's approval of lenacapavir?
- Who is eligible for lenacapavir under SAHPRA's approval?
- How will lenacapavir be distributed in South Africa?
- What safety data supports the twice-yearly injection schedule?
SAHPRA approved lenacapavir for HIV pre-exposure prophylaxis (PrEP) in October 2025, making South Africa the first African nation to register this twice-yearly injectable. The capsid inhibitor demonstrated 100% efficacy in the Phase 3 PURPOSE 1 trial and offers a transformative alternative to daily oral regimens for a country bearing the world's highest HIV burden.
Contents9 sections
Key Takeaways
- Regulatory milestone: SAHPRA granted full registration approval for lenacapavir on October 27, 2025, for adults and adolescents weighing at least 35 kg, based on data from the Phase 3 PURPOSE 1 and PURPOSE 2 trials (Gilead Sciences).
- Clinical efficacy: PURPOSE 1 reported zero HIV infections among 2,134 cisgender women receiving lenacapavir (0 per 100 person-years; 95% CI, 0.00 to 0.19), showing superiority over daily oral tenofovir/emtricitabine and background HIV incidence (PURPOSE 1).
- Dosing innovation: The subcutaneous injection administered every six months eliminates daily pill burden, addressing adherence challenges that limit real-world effectiveness of oral PrEP in South Africa.
- Access strategy: Gilead is supplying lenacapavir at no profit through the Global Fund and PEPFAR, with voluntary licensing agreements enabling large-scale generic rollout anticipated by 2027 (South Africa market).
- Market impact: South Africa's 7.7 million people living with HIV represent the largest national epidemic globally, creating urgent demand for prevention tools that overcome adherence barriers.
What Is Lenacapavir and How Does It Work?
Lenacapavir belongs to a novel drug class: the HIV-1 capsid inhibitors. Unlike reverse transcriptase inhibitors or integrase inhibitors that target enzymatic steps in viral replication, lenacapavir disrupts the viral capsid protein. This mechanism interferes with multiple stages of the HIV lifecycle, including capsid assembly, viral entry, and nuclear import of viral genetic material.
The extended half-life of lenacapavir supports its six-month dosing interval. Pharmacokinetic studies demonstrate sustained plasma concentrations sufficient to maintain preventive efficacy over 26-week intervals between subcutaneous injections. For patients, this means protection without the cognitive load of daily medication adherence.
Gilead Sciences developed lenacapavir over nearly two decades. The compound received FDA approval as Yeztugo on June 18, 2025, making it the first and only twice-yearly HIV prevention option available in the United States. SAHPRA's approval followed closely, positioning South Africa as an early adopter among high-burden countries.
What Clinical Evidence Supports SAHPRA's Decision?
SAHPRA's approval drew on data from two Phase 3 randomized controlled trials: PURPOSE 1 and PURPOSE 2.
The PURPOSE 1 trial (NCT04994509) enrolled 5,338 initially HIV-negative cisgender women and adolescent girls in South Africa and Uganda. Participants were randomized in a 2:2:1 ratio to receive subcutaneous lenacapavir every 26 weeks, daily oral emtricitabine-tenofovir alafenamide (F/TAF), or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF). The results were remarkable: zero HIV infections occurred among 2,134 participants in the lenacapavir group (0 per 100 person-years; 95% confidence interval, 0.00 to 0.19). By comparison, the F/TAF group saw 39 infections (2.02 per 100 person-years) and the F/TDF group saw 16 infections (1.69 per 100 person-years). Lenacapavir demonstrated superiority over both background HIV incidence (incidence rate ratio, 0.00; 95% CI, 0.00 to 0.04; P<0.001) and F/TDF (incidence rate ratio, 0.00; 95% CI, 0.00 to 0.10; P<0.001).
The PURPOSE 2 trial (NCT04925752) evaluated lenacapavir among cisgender men, transgender men, and transgender women across diverse geographic regions. Among 2,179 participants receiving lenacapavir, 99.9% remained HIV-negative. Together, these trials provided the solid evidence base for SAHPRA's regulatory decision.
Safety data from both trials showed no significant new concerns. Injection-site reactions occurred more frequently with lenacapavir (68.8%) than placebo injections (34.9%), though only 0.2% of participants discontinued due to these reactions. Adherence to daily oral F/TAF and F/TDF in the trials was low, underscoring the real-world challenge that lenacapavir's extended dosing interval addresses.
Who Is Eligible for Lenacapavir in South Africa?
SAHPRA approved lenacapavir for HIV pre-exposure prophylaxis in adults and adolescents weighing at least 35 kg. The weight threshold ensures adequate pharmacokinetic exposure and safety in younger populations. Healthcare providers must assess individual risk factors for HIV acquisition before prescribing.
The approved indication covers pre-exposure prophylaxis for sexually acquired HIV infection. Lenacapavir is not indicated for treatment of established HIV infection or for post-exposure prophylaxis. Patients must be HIV-negative before initiating and must receive testing at regular intervals during treatment.
As a prescription medication, lenacapavir requires administration by healthcare professionals trained in subcutaneous injection technique. The injection is given in the abdomen, and patients must maintain scheduled appointments every six months to ensure continuous protection.
How Will Lenacapavir Reach Patients in South Africa?
Access to lenacapavir in South Africa will depend on government procurement decisions, pricing negotiations, and integration into national prevention programs. Private healthcare providers may offer the drug through insurance schemes or out-of-pocket payment.
Gilead Sciences has structured an access strategy specifically for low- and middle-income countries. The company is supplying lenacapavir at no profit in coordination with the Global Fund and the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). These partners, which already support the majority of HIV prevention services in resource-limited settings, lead country prioritization and implementation.
Gilead has also finalized voluntary licensing agreements with six generic manufacturers—Dr. Reddy's Laboratories, Emcure, Eva Pharma, Ferozsons Laboratories, Hetero, and Mylan (a Viatris subsidiary). These agreements cover 120 high-incidence, resource-limited countries. Large-scale generic rollout is anticipated by 2027, enabling sustainable long-term supply at affordable prices.
South Africa is among 18 priority countries representing 70% of the global HIV burden that Gilead is prioritizing for registration. This group includes Botswana, Eswatini, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Nigeria, Philippines, Rwanda, Tanzania, Thailand, Uganda, Vietnam, Zambia, and Zimbabwe.
What Safety Profile Supports Twice-Yearly Dosing?
The safety database supporting lenacapavir includes data from the Phase 3 PURPOSE 1 and PURPOSE 2 trials. No significant or new safety concerns emerged during the study periods.
| Adverse Event | Lenacapavir Group | Placebo Injection Group |
|---|---|---|
| Injection-site reactions | 68.8% | 34.9% |
| Discontinuation due to injection-site reactions | 0.2% | Not reported |
| Serious adverse events | Low incidence | Comparable |
The pharmacokinetic profile of lenacapavir supports the extended dosing interval. Drug concentrations remain above therapeutic thresholds for the full six-month period between injections. This sustained exposure enables the convenience of twice-yearly administration while maintaining protective efficacy.
Real-world safety monitoring will continue post-approval. SAHPRA's pharmacovigilance system will collect data on adverse events as the drug enters broader clinical use. Healthcare providers play a critical role in reporting any safety signals that emerge during routine clinical practice.
What Impact Could Lenacapavir Have on South Africa's HIV Epidemic?
South Africa carries the world's largest HIV burden, with an estimated 7.7 million people living with the virus. Despite decades of prevention efforts, new infections continue at unacceptably high rates. Adherence to daily oral PrEP in South Africa and other sub-Saharan African countries has ranged from 40% to 70%, limiting real-world protective efficacy.
Lenacapavir's twice-yearly dosing addresses this fundamental barrier. By eliminating daily pill burden, the injectable format removes a major obstacle to consistent protection. Population-level impact will depend on uptake rates, pricing accessibility, and successful integration into national prevention programs.
The approval positions South Africa as a regional leader in adopting novel HIV prevention technologies. Regulatory decisions by SAHPRA may influence other African nations considering lenacapavir approval. Harmonized approval standards across the region could accelerate access for millions at risk.
What to watch next: Market uptake will depend on whether government procurement programs and private insurance schemes adopt lenacapavir into their PrEP formularies, and at what cost-sharing level for patients. Real-world effectiveness studies will generate data on adherence patterns, injection-site reactions, and population-level impact on HIV incidence.
Frequently Asked Questions
What is lenacapavir and how does it differ from daily oral PrEP?
Lenacapavir is a first-in-class HIV-1 capsid inhibitor that disrupts viral replication by targeting the capsid protein. Unlike daily oral PrEP regimens such as tenofovir/emtricitabine, lenacapavir is administered as a subcutaneous injection every six months, providing continuous protection without daily pill burden.
What clinical evidence supports SAHPRA's approval of lenacapavir?
SAHPRA's approval was based on the Phase 3 PURPOSE 1 and PURPOSE 2 trials. In PURPOSE 1, zero HIV infections occurred among 2,134 cisgender women receiving lenacapavir (0 per 100 person-years). In PURPOSE 2, 99.9% of participants remained HIV-negative. Both trials demonstrated superiority over daily oral tenofovir/emtricitabine and background HIV incidence.
Who is eligible for lenacapavir under SAHPRA's approval?
SAHPRA approved lenacapavir for adults and adolescents weighing at least 35 kg for HIV pre-exposure prophylaxis. The weight threshold ensures adequate pharmacokinetic exposure and safety in younger populations. Healthcare providers assess individual risk factors before prescribing.
How will lenacapavir be distributed in South Africa?
Gilead Sciences is providing lenacapavir at no profit to the company in coordination with the Global Fund and PEPFAR. These partners lead country prioritization and implementation through existing platforms. Gilead has also established voluntary licensing agreements with six generic manufacturers to enable large-scale affordable supply by 2027.
What safety data supports the twice-yearly injection schedule?
Phase 3 trials found no significant or new safety concerns with lenacapavir. Injection-site reactions occurred in 68.8% of participants versus 34.9% in the placebo injection group, with only 0.2% discontinuing due to these reactions. The pharmacokinetic profile supports sustained plasma concentrations over six-month intervals.
Primary Sources
- Bekker LG, et al. "Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women." New England Journal of Medicine. July 24, 2024. doi: 10.1056/NEJMoa2407001. https://www.nejm.org/doi/full/10.1056/NEJMoa2407001
- Gilead Sciences. "Yeztugo (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection." June 18, 2025. https://www.gilead.com/news/news-details/2025/...
- ClinicalTrials.gov. "PURPOSE 1: Lenacapavir for PrEP in Cisgender Women." NCT04994509. https://clinicaltrials.gov/study/NCT04994509
- ClinicalTrials.gov. "PURPOSE 2: Lenacapavir for PrEP in Cisgender Men and Gender-Diverse People." NCT04925752. https://clinicaltrials.gov/study/NCT04925752
- Gilead Sciences. "Access Strategy for Lenacapavir for PrEP in Low- and Middle-Income Countries." https://www.gilead.com/responsibility/...
Continue Exploring
Jump into the entities behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
